XFCT-MRI hybrid multimodal contrast agents for complementary imaging

Nanoscale. 2023 Feb 2;15(5):2214-2222. doi: 10.1039/d2nr05829d.

Abstract

Multimodal contrast agents in biomedical imaging enable the collection of more comprehensive diagnostic information. In the present work, we design hybrid ruthenium-decorated superparamagnetic iron oxide nanoparticles (NPs) as the contrast agents for both magnetic resonance imaging (MRI) and X-ray fluorescence computed tomography (XFCT). The NPs are synthesized via a one-pot polyol hot injection route, in diethylene glycol. In vivo preclinical studies demonstrate the possibility of correlative bioimaging with these contrast agents. The complementarity allows accurate localization, provided by the high contrast of the soft tissues in MRI combined with the elemental selectivity of XFCT, leading to NP detection with high specificity and resolution. We envision that this multimodal imaging could find future applications for early tumor diagnosis, improved long-term treatment monitoring, and enhanced radiotherapy planning.

MeSH terms

  • Contrast Media*
  • Fluorescence
  • Magnetic Iron Oxide Nanoparticles
  • Magnetic Resonance Imaging / methods
  • Tomography, X-Ray Computed* / methods

Substances

  • Contrast Media